GTS 21

Drug Profile

GTS 21

Alternative Names: DMXB-A; DMXB-A sustained release; DMXB-A-SR

Latest Information Update: 15 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taiho Pharmaceutical; University of Florida
  • Developer CoMentis
  • Class Benzylidene compounds; Neuroprotectants; Nootropics; Pyridines; Small molecules
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Attention-deficit hyperactivity disorder
  • Discontinued Alzheimer's disease; Cognition disorders

Most Recent Events

  • 28 Apr 2015 University of Florida plans a phase II trial for Smoking withdrawal in USA (NCT02432066)
  • 04 Apr 2014 University of Colorado at Denver plans a phase I trial for Autistic disorder in USA (NCT02111551)
  • 07 Apr 2008 GTS 21 is still in Phase-I/II trials for Attention deficit hyperactivity disorder in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top